Create Sd Holdings Co., Ltd. · TSE:3148
Create Sd — H1 FYE May 2021 Earnings Presentation
21 slides from Create Sd's earnings presentation, Jan 20, 2021
Slide 1: Financial Results for Q2 of FYE May 2021
Financial Results for Q2 of FYE May 2021 (June 1, 2020 to November 30, 2020) January 20, 2021 The earnings forecasts in this document are based on the business environment as of the time of writing. Actual results may differ from projections due to a variety of factors. Note also that inquiries shou
Slide 2: Agenda
Consolidated Results for H1 of FYE May 2021 1. Statement of Income 2. Balance Sheet 3. Store Openings/Closings (Non-Consolidated) 4. Performance Highlights (Non-Consolidated) Initiatives in H2 of FYE May 2021 1. New Store Openings/Renovation of Existing Stores 2. Our COVID-19 Response 3. Productivit
Slide 3: Consolidated Results for H1 of FYE May 2021
Consolidated Results for H1 of FYE May 2021 3
Slide 4: 1. Consolidated Statement of Income for H1 of FYE May 2021
1. Consolidated Statement of Income for H1 of FYE May 2021 FYE May 2020 FYE May 2021 H1 Results H1 Results YoY (Millions of yen) Share (Millions of yen) Share Vs plan (%) (%) change (%) (%) Net sales 153,305 100.0 168,671 100.0 110.0 101.9 Gross profit 42,027 27.4 46,407 27.5 110.4 102.8 SG&A expens
Slide 5: 2. Consolidated Balance Sheet for H1 of FYE May 2021
2. Consolidated Balance Sheet for H1 of FYE May 2021 (Millions of yen) May 31, 2020 Nov. 30, 2020 Change Total assets 153,423 157,194 +3,770 Current assets 87,162 87,285 +123 Non-current assets 66,261 69,908 +3,647 Total liabilities 66,646 64,972 –1,674 Current liabilities 59,595 57,666 –1,929 Non-c
Slide 6: 3. Store Openings/Closings (Non-Consolidated)
3. Store Openings/Closings (Non-Consolidated) Store openings/closings and renovations ・Store openings: 19 drug stores / 8 prescription drug stores Kanagawa Tokyo Chiba Ibaraki Aichi Total Store Drug stores 11 5 1 0 2 19 opening Prescription drug 4 3 0 1 0 8 stores Store closings: 3 drug stores (1 fo
Slide 7: 3. Store Openings/Closings (Non-Consolidated)
3. Store Openings/Closings (Non-Consolidated) Store openings in collaboration with fresh produce category ■Store openings: 3 stores (8 stores as of November 30, 2020) Note:format One of these was converted from existing through expansion and renovation. Kohoku Tsunashima-Higashi (Kanagawa) Shin-Yoko
Slide 8: 4. Performance Highlights: Monthly trend in sales at existing stores
4. Performance Highlights (Non-Consolidated) Net sales —Monthly trend in sales at existing stores— ■All stores: Up 8.7% YoY (Up 1.9% vs. target) Existing stores: Up 4.1% YoY (OTC: Up 3.8%; prescription: Up 6.8%) ・Sales per customer up due primarily to increased demand for products related to prevent
Slide 9: 4. Performance Highlights: Net sales by segment
4. Performance Highlights (Non-Consolidated) Net sales —Net sales by segment— ・Increased demand in categories related to COVID-19 ・Prescriptions up 0.1 pts to 9.2% as a percentage of sales FYE May 2020 FYE May 2021 H1 Results H1 Results Net sales Net sales Share (%) Share (%) YoY change (%) (million
Slide 10: 4. Performance Highlights: Gross profit margin/SG&A ratio
4. Performance Highlights (Non-Consolidated) Gross profit margin/SG&A ratio ■Gross profit margin: 27.7% Up 0.1 pts YoY Up 0.2 pts vs target ・Prescriptions were up as a percentage of sales ・Gross profit margin improved with voluntary suspension of sales promotions ・Gross profit margin improved with i
Slide 11: 4. Performance Highlights: Dispensing department
4. Performance Highlights (Non-Consolidated) Dispensing department —Net sales/No. of prescriptions/prescription unit price — ■Sales at all stores: Up 10.1% YoY Sales at existing stores: Up 6.8% YoY ・Number of prescriptions down due to fewer exams and longer-term prescriptions, but prescription unit
Slide 12: 4. Performance Highlights: Prescription drug store department
4. Performance Highlights (Non-Consolidated) Prescription drug store department —Home-based dispensing services/premiums— ■Expansion of home-based dispensing services ・No. of stores offering home-based dispensing services at year end: 152 stores (up 20 from previous year) ・No. of patients supported
Slide 13: Initiatives in H2 of FYE May 2021
Initiatives in H2 of FYE May 2021 13
Slide 14: 1. New Store Openings/Renovation of Existing Stores
1. New Store Openings/Renovation of Existing Stores Store openings/closings and renovations Drug stores 641 —H2 forecast— In-store pharmacies 201 ■Drug stores: 21 stores Rate of in-store pharmacies 31.4% Nov. 30, 2020 (Full-year total: 40 stores) No. of stores Dedicated prescription 36 ・Continue pur
Slide 15: 2. Our COVID-19 Response
2. Our COVID-19 Response Peri-/Post-COVID-19 Sales Measures ■Strengthening of EDLP and PB ・Price of around 1,500 items lowered gradually Lowering of starting in July prices ⇒Plan is to continue gradually expanding items ・Continue voluntary suspension of sales promotions that bring in customers on sp
Slide 16: 3. Productivity Improvement
3. Productivity Improvement Efforts to improve operational efficiency ■Enhancement of productivity through introduction of semi-self-checkout registers ・Introduced at 22 stores as of November 30, 2020, will continue to promote further introduction ■Optimization of working hours through control of ma
Slide 17: 4. Enhanced Professionalism
4. Enhanced Professionalism Prescription drug store department ■Expansion of pharmacies partnered with regional medical institutions Nov. 30, 2020 May 31, 2021 (Target) ・Train “family pharmacists” "Family pharmacists" 118 ⇒ 200 Stores offering home- ・Establishment of structure for expanding based se
Slide 18: 5. Promotion of Digital Transformation (DX)
5. Promotion of Digital Transformation (DX) Improvement of customer experience using digital tools Respond to changes in society and develop stronger, longer lasting relationships by providing optimal methods/services to each customer and patient ■Establishment of new department specializing in cust
Slide 19: Revised FYE May 2021 Plan
Revised FYE May 2021 Plan 19
Slide 20: 1. Key Points of Revised Plan for Consolidated Performance
1. Key Points of Revised Plan for Consolidated Performance Assumptions of revised plan ■Initial plan ・Impact of COVID-19 expected to remain (even if decreasing) through H1 (November 2020) ■Revised plan ・Impact of COVID-19 will continue beyond H2, and situation will remain uncertain Revised full-year
Slide 21: 2. Revised FYE May 2021 Plan (Consolidated)
2. Revised FYE May 2021 Plan (Consolidated) FYE May 2020 FYE May 2021 (Results) (Revised plan) Share Share YoY change (Millions of yen) (Millions of yen) (%) (%) (%) Net sales 319,588 100.0 338,330 100.0 105.9 Gross profit 88,986 27.8 93,000 27.5 104.5 SG&A expenses 71,192 22.3 75,140 22.2 105.5 Ope
Create SD Holdings — H1 FYE May 2021 Earnings Presentation on 6ix